Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GA | ISIN: BMG0360L1349 | Ticker-Symbol:
NASDAQ
28.03.24
16:28 Uhr
2,325 US-Dollar
+0,015
+0,65 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALTAMIRA THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ALTAMIRA THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur ALTAMIRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoWhy Altamira Therapeutics Stock Is Racing Higher2
MoAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines435HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira's SemaPhore nanoparticlesTargeting safer and accessible mRNA vaccines ...
► Artikel lesen
07.02.Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal-
07.02.Altamira Therapeutics Ltd: Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal266HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when...
► Artikel lesen
24.01.Altamira Therapeutics stock jumps 7% as it files for second patent1
24.01.Altamira Therapeutics Ltd: Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment154HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira's polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer...
► Artikel lesen
19.01.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer2
08.01.Altamira Therapeutics files to sell 162.5K shares3
08.01.Altamira Therapeutics Ltd: Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit2
29.12.23Altamira Therapeutics Ltd: Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement259HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based...
► Artikel lesen
29.12.23Altamira Therapeutics stock rises after it regains compliance with Nasdaq2
11.12.23Why Altamira Therapeutics (CYTO) Stock Is Down 50% Today15
11.12.23Altamira Therapeutics Ltd: Altamira Therapeutics Provides Investor and Business Update205HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to...
► Artikel lesen
08.12.23Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer4
05.12.23Altamira Therapeutics Ltd: Altamira Therapeutics to Host Investor & Business Update Call on December 11th8
29.11.23Altamira Therapeutics Ltd: Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement7
27.11.23Why Is Altamira Therapeutics (CYTO) Stock Down 8% Today?6
21.11.23Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer3
17.11.23Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today?11
17.11.23Altamira Therapeutics Ltd: Altamira Therapeutics Announces Partial Spin-Off of Bentrio Business365Initiates Strategic Repositioning to Focus on Company's Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1